HC Wainwright restated their buy rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note issued to investors on Tuesday morning. They currently have a $17.00 price objective on the biopharmaceutical company’s stock.
“a Highly Favorable Risk/Reward; Affirm Buy Stock Data 02/05/2018 Price $5.19 Exchange NASDAQ Price Target $17.00 52-Week High $9.93 52-Week Low $4.04 Enterprise Value (M) $106.6 Market Cap (M) $268 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 477,304 Short Interest (M) 2.97 Shares Outstanding (M): Figure shown is as of January 24, 2018. Balance Sheet Metrics Cash (M) $161.4 Total Debt (M) $0.0 Total Cash/Share $3.13 Book Value/Share $2.78 Cash (M): Figure shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.46) (0.79)A (0.56) 2Q (0.47) (0.83)A (0.55) 3Q (0.58) (0.63)A (0.54) 4Q (0.61) (0.60) (0.52) FY (2.11) (2.80) (2.17) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 2.0 1.5A 1.5 2Q 1.2 1.6A 1.0 3Q 0.9 4.1A 1.2 4Q 1.1 2.0 1.5 FY 5.1 9.1 5.2 10 8 6 4 2 FEB- 17 J UN- 17 OCT- 17 FEB- 18 20 15 10 5 0 Vol. (mil) Price cUTI: We believe IGNITE3 will be a solid, clean win.”,” HC Wainwright’s analyst wrote.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, January 12th. BidaskClub cut Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, February 2nd. Finally, ValuEngine cut Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $15.15.
In related news, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jacques Dumas sold 7,167 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its holdings in Tetraphase Pharmaceuticals by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 874 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 3,104 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Tetraphase Pharmaceuticals by 6.9% in the 2nd quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 3,800 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Tetraphase Pharmaceuticals by 2.0% in the 2nd quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock valued at $1,727,000 after purchasing an additional 4,800 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Tetraphase Pharmaceuticals by 3.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 194,144 shares of the biopharmaceutical company’s stock valued at $1,384,000 after purchasing an additional 6,247 shares in the last quarter. 58.36% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/10/hc-wainwright-reiterates-buy-rating-for-tetraphase-pharmaceuticals-ttph.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.